or Try an Advanced Search...

    Technical Analysis for NRSNW - NeuroSense Therapeutics Ltd. - warrant

    Grade Last Price % Change Price Change
    F 0.20 -2.91% -0.01
    NRSNW closed down 2.91 percent on Monday, July 1, 2024, on 56 percent of normal volume.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical NRSNW trend table...
    Date Alert Name Type % Chg
    20 DMA Support Bullish 0.00%
    Wide Bands Range Expansion 0.00%
    200 DMA Resistance Bearish -2.91%
    Pocket Pivot Bullish Swing Setup -2.91%
    Wide Bands Range Expansion -2.91%
    Gapped Up Strength -2.91%
    MACD Bearish Centerline Cross Bearish 11.98%
    Narrow Range Bar Range Contraction 11.98%
    Wide Bands Range Expansion 11.98%
    Fell Below 200 DMA Bearish 11.98%
    Older End-of-Day Signals for NRSNW ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Previous Day's High 3 days ago
    Rose Above 200 DMA 3 days ago
    Rose Above 50 DMA 3 days ago
    Rose Above 10 DMA 3 days ago
    2x Volume Pace 3 days ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    NRSNW Chart by TradingView
    Basic chart:

    Profile

    NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. Its lead product is PrimeC, an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Alzheimer's Disease Parkinson's Disease Neurodegenerative Diseases Amyotrophic Lateral Sclerosis Treatment Of Parkinson's Disease Senescence Treatment Of Alzheimer's Disease Neurodegenerative Disease Clinical Neuroscience

    Is NRSNW a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 24 NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results
    Jun 21 NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal
    May 14 NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning
    May 2 NeuroSense Announces First Quarter 2024 Business Update
    Apr 22 NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
    Apr 18 NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
    Apr 12 NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
    Apr 10 NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
    Apr 9 NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics
    Feb 21 NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
    See more NRSNW news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 0.55
    52 Week Low 0.073
    Average Volume 6,041
    200-Day Moving Average 0.21
    50-Day Moving Average 0.24
    20-Day Moving Average 0.18
    10-Day Moving Average 0.21
    Average True Range 0.03
    RSI (14) 49.75
    ADX 14.69
    +DI 36.67
    -DI 35.14
    Chandelier Exit (Long, 3 ATRs) 0.15
    Chandelier Exit (Short, 3 ATRs) 0.20
    Upper Bollinger Bands 0.26
    Lower Bollinger Band 0.10
    Percent B (%b) 0.6
    BandWidth 87.02
    MACD Line 0.00
    MACD Signal Line 0.00
    MACD Histogram 0.0039
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.23
    Resistance 3 (R3) 0.23 0.21 0.23
    Resistance 2 (R2) 0.21 0.21 0.22 0.22
    Resistance 1 (R1) 0.21 0.20 0.21 0.21 0.22
    Pivot Point 0.19 0.19 0.20 0.20 0.19
    Support 1 (S1) 0.19 0.19 0.19 0.19 0.18
    Support 2 (S2) 0.17 0.18 0.18 0.18
    Support 3 (S3) 0.17 0.17 0.18
    Support 4 (S4) 0.17